Literature DB >> 1469417

Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis)

C J Fowler1, P E van Kerrebroeck, A Nordenbo, H Van Poppel.   

Abstract

Bladder symptoms in patients with multiple sclerosis (MS) are common and usually arise as a result of spinal lesions which interrupt the neural pathways connecting the pontine micturition centre to the sacral spinal cord. Thus these symptoms are particularly likely to occur in those with lower limb neurological deficits. Fortunately bladder dysfunction in MS is rarely associated with serious upper tract disease so that the problem is usually one of symptomatic management. Lower urinary tract symptoms may be both "irritative" or "obstructive" in nature and can be explained in terms of underlying detrusor hyperreflexia and incomplete bladder emptying. Treatment is aimed at minimising both these effects. Oral anticholinergic medication can be effective in reducing detrusor hyperreflexia and intermittent catheterisation is used to reduce abnormally high post micturition residual volumes. With this simple treatment, often used in combination, many less severely affected patients with MS can gain considerable improvement in controlling urinary continence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469417      PMCID: PMC1015278          DOI: 10.1136/jnnp.55.11.986

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  LESIONS ON THE ANTERIOR FRONTAL LOBES AND DISTURBANCES OF MICTURITION AND DEFAECATION.

Authors:  J ANDREW; P W NATHAN
Journal:  Brain       Date:  1964-06       Impact factor: 13.501

2.  PARAPLEGIA OF NON-TRAUMATIC ORIGIN AND DISSEMINATED (MULTIPLE) SCLEROSIS: URINARY COMPLICATIONS, THEIR NATURE AND TREATMENT.

Authors:  M DAMANSKI; A SUTCLIFFEKEER
Journal:  Acta Neurol Psychiatr Belg       Date:  1964-05

3.  MANAGEMENT OF UPPER URINARY TRACT COMPLICATIONS IN MULTIPLE SCLEROSIS BY MEANS OF URINARY DIVERSION TO AN ILEAL CONDUIT.

Authors:  W SAMELLAS; B RUBIN
Journal:  J Urol       Date:  1965-05       Impact factor: 7.450

4.  Spinal cord organization of micturition reflex afferents.

Authors:  W E Bradley; C T Teague
Journal:  Exp Neurol       Date:  1968-12       Impact factor: 5.330

5.  Vesical dysfunction in multiple sclerosis.

Authors:  S E Gonor; D J Carroll; J B Metcalfe
Journal:  Urology       Date:  1985-04       Impact factor: 2.649

6.  Cystometric response to propantheline in detrusor hyperreflexia: therapeutic implications.

Authors:  J G Blaivas; K B Labib; S J Michalik; A A Zayed
Journal:  J Urol       Date:  1980-08       Impact factor: 7.450

7.  Long-term alpha-adrenergic-blocking therapy in detrusor-urethra dyssynergia.

Authors:  R L Vereecken; H Van Poppel; G Boeckx; A Leruitte
Journal:  Eur Urol       Date:  1983       Impact factor: 20.096

8.  Clinical pharmacology of terodiline.

Authors:  K E Andersson
Journal:  Scand J Urol Nephrol Suppl       Date:  1984

9.  Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia.

Authors:  J B Gajewski; S A Awad
Journal:  J Urol       Date:  1986-05       Impact factor: 7.450

10.  Detrusor-external sphincter dyssynergia: a detailed electromyographic study.

Authors:  J G Blaivas; H P Sinha; A A Zayed; K B Labib
Journal:  J Urol       Date:  1981-04       Impact factor: 7.450

View more
  13 in total

1.  Urologic manifestations of multiple sclerosis: proposed treatment algorithms.

Authors:  G A Barbalias; E N Liatsikos; C Passakos; D Barbalias; G Sakelaropoulos
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Clinical management of the neurourological syndrome associated with multiple sclerosis and correlations to grade of the disease.

Authors:  G A Barbalias; E N Liatsikos; C Passakos; D Barbalias; G Sakelaropoulos
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 3.  Constipation in neurological diseases.

Authors:  K Winge; D Rasmussen; L M Werdelin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

4.  The TRUST (EvaluaTion of Bladder Function in Relapsing-Remitting MUltiple Sclerosis Patients Treated with Natalizumab) Observational Study.

Authors:  Bhupendra O Khatri; John F Foley; Jennifer Fink; John F Kramer; Choon Cha; Xiaojun You; John D Warth; Pam Foulds
Journal:  Int J MS Care       Date:  2014

5.  Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. European Group on SUDIMS.

Authors:  A Nordenbo; P Van Kerrebroeck; H Van Poppel; C J Fowler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

6.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 7.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 8.  Multiple sclerosis therapy. A practical guide.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 9.  [Diagnosis of neurogenic bladder dysfunction].

Authors:  A Kaufmann; I Kurze
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 10.  Autonomic dysfunction in multiple sclerosis.

Authors:  Carl-Albrecht Haensch; Johannes Jörg
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.